Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Details)

v3.21.1
Segment Information (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
segment
Mar. 31, 2020
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 2  
Segment Reporting Information [Line Items]    
Total revenue $ 115,533 $ 106,030
Total cost of revenue 73,959 59,661
Total gross profit 41,574 46,369
General and administrative 40,476 36,344
Research and development 2,456 2,060
Sales and marketing 13,749 13,258
Total operating expenses 56,681 51,662
Loss from operations (15,107) (5,293)
Interest expense, net 1,177 819
Other expense (income), net 4,854 (223)
Loss before taxes (21,138) (5,889)
Income tax expense 976 1,089
Net loss (22,114) (6,978)
PCR testing, write-offs, COVID-19 5,300  
Clinical Services    
Segment Reporting Information [Line Items]    
Total revenue 96,487 92,982
Total cost of revenue 61,565 48,923
Total gross profit 34,922 44,059
PCR testing, write-offs, COVID-19 5,300  
Pharma Services    
Segment Reporting Information [Line Items]    
Total revenue 19,046 13,048
Total cost of revenue 12,394 10,738
Total gross profit $ 6,652 $ 2,310